Treatment patterns of adjuvant interferon-α2b for high-risk melanoma: a retrospective study of the Grupo Español Multidisciplinar de Melanoma - Prima study
Espinosa E (1), Soriano V, Malvehy J, Berrocal A, Martínez de Prado P, Quindós M, Soria A, Márquez-Rodas I, Palacio I, Cerezuela P, López-Vivanco G, Alonso L, Samaniego E, Ballesteros A, Puértolas T, Díaz-Beveridge R, de la Cruz-Merino L, López Castro R, López López R, Stevinson K, Del Barrio P, Tornamira MV, Guillém V, Martín-Algarra S. (1a) Medical Oncology Service, Hospital Universitario La Paz (b) Medical Oncology Service, Hospital Ramón y Cajal (c) Medical Oncology Service, Instituto de Investigación Sanitaria Gregorio Marañon (d)Medical Oncology Service, Hospital La Princesa (e) Medical Affairs, Merck Sharp & Dohme, Madrid (f) Medical Oncology Service, Instituto Valenciano de Oncología (g) Medical Oncology Service, Hospital General Universitario de Valencia (h) Medical Oncology Service, Hospital La Fe, Valencia (i) Medical Oncology Service, Hospital Clinic de Barcelona, Barcelona (j) Medical Oncology Service, Hospital de Basurto, Bilbao (k) Medical Oncology Service, Hospital Teresa Herrera, La Coruña (l) Medical Oncology Service, Hospital Central de Asturias, Oviedo (m) Medical Oncology Service, Hospital General Universitario Santa Lucía, Cartagena (n) Medical Oncology Service, Hospital de Cruces, San Vicente de Baracaldo (o) Medical Oncology Service, Hospital Universitario Virgen de la Victoria, Málaga (p) Dermatology Service, Complejo Asistencial Universitario de León, León (q) Medical Oncology Service, Hospital Miguel Servet, Zaragoza (r) Medical Oncology Service, Hospital Virgen de la Macarena, Sevilla (s) Medical Oncology Service, Hospital Clínico Universitario de Valladolid, Valladolid (t) Medical Oncology Service, Hospital Clínico Universitario de Santiago, Santiago de Compostela (u) Medical Oncology Service, Clínica Universitaria de Navarra, Pamplona, Spain (v) Global Health Outcomes Research, Merck Sharp & Dohme, Kenilworth, New Jersey, USA.
Revista: Melanoma Research
Fecha: 09-mar-2016Oncología Médica
Adjuvant interferon-α2b (IFN-α2b) has been studied extensively in clinical trials, but there have been few studies of real-world use.
The aim of this study is to describe the IFN-α2b real-world patterns in patients with high-risk melanoma in Spain. This was a retrospective and multicentre chart review study of an unselected cohort of patients with melanoma at high risk for relapse (stage IIB/IIC/III) treated with IFN-α2b. Patterns were assessed in terms of dose and compliance to planned treatment.
A survival analysis was carried out for the full population and according to Kirkwood scheme compliance and the presence of ulceration. Of 327 patients treated with IFN-α2b, 318 received a high-dose regimen following the standard Kirkwood scheme; thus, patterns are described for this regimen.
A total of 121 (38%) and 88 (28%) patients had at least one dose reduction during the induction and maintenance phases, respectively. Dose delay was required in fewer than 10% of patients. A total of 78, 40 and 38% of the patients completed the induction phase, maintenance phase and completed treatment, respectively.
The median progression-free and overall survival for the full population were 3.2 and 10.5 years, respectively. There were no differences in progression-free survival and overall survival according to Kirkwood scheme compliance and the presence of ulceration.
The most frequent adverse events were neutropenia (31%) and fatigue (30%). High-dose IFN-α2b is the most frequently used regimen in Spain as an adjuvant systemic treatment for high-risk melanoma. Despite poor compliance, in this retrospective study, IFN-α2b treatment provided a benefit consistent with that described previously.
CITA DEL ARTÍCULO Melanoma Res. 2016 Mar 9.
tal vezLE INTERESE
La Clínica es el hospital privado con mayor dotación tecnológica de España, todo en un único centro.
Los profesionales de la Clínica realizan una labor continuada de investigación y formación, siempre en beneficio del paciente.
Conozca por qué somos diferentes a otros centros sanitarios. Calidad, rapidez, comodidad y resultados.